Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
Abstract XPO1 has recently emerged as a viable treatment target for solid malignancies, including glioblastoma (GBM), the most common primary malignant brain tumor in adults. However, given that tumors become commonly resistant to single treatments, the identification of combination therapies is cri...
Guardado en:
Autores principales: | Enyuan Shang, Yiru Zhang, Chang Shu, Chiaki Tsuge Ishida, Elena Bianchetti, Mike-Andrew Westhoff, Georg Karpel-Massler, Markus D. Siegelin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ba23ac173ed440d99429cc6ecf60572d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Yiru Zhang, et al.
Publicado: (2018) -
Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
por: Georg Karpel-Massler, et al.
Publicado: (2017) -
Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials
por: Yali Tao, et al.
Publicado: (2021) -
Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E
por: Jack G. Fisher, et al.
Publicado: (2021) -
Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Reut Yosef, et al.
Publicado: (2016)